Gilead Sciences, Inc. (NASDAQ:GILD) has announced that following the initiation of a review, concerning Zydelig, the company is going to halt a number of patient studies of the drug. Zydelig had initially been cleared for patient studies, but patients enrolled in the trial had started to exhibit development of infections, resulting in death.

The company had revealed that the signs were particularly common in patients undergoing late-stage testing. The patients were mostly suffering from lymphocytic leukemia and non-Hodgkin’s lymphoma. Consequently, the latter set of patients already had a damaged lymphatic-infection fighting system. Gilead Sciences has not yet disclosed the complete details of the unfortunate events and is still to update on the number of deaths.

A spokesman for the company, Nathan Kaiser, stated that the company would be reviewing all ongoing studies and will also collaborate with the regulatory bodies, regarding the matter. However, an earlier report on the matter had identified that the effects were observed in three particular studies, which were aimed at testing Zydelig in combination with other drugs. The reports had also identified that combinations of CLL treatments were not yet approved and the NHL patients had different characteristics, from the approved indications.

Currently, the regulatory bodies do not seem to be targeting Zydelig in particular, since the guidance issued by these bodies have stated that if the drug is found to be well tolerated in patients, it should not be stopped. Added to this, the guidance also states that the patients should be monitored for any signs of infections, after having the drug administered. Zydelig was responsible for generating $132 million, in sales, during 2015. Even though the drug has already been approved to be taken in combination with Rituxan, the EU regulatory would be reviewing the data from current studies to revaluate the initial decision.

Gilead Sciences, Inc. (NASDAQ:GILD) closed at a share price of $89.44, at the end of the March 15 trading session, after having a trade volume of 10.27 million and losing 1.13% of its share value.

Previous articleCaladrius Biosciences Inc (NASDAQ:CLBS)’s Subsidiary PCT, LLC Collaborates With Hitachi Chemical
Next articlePTC Therapeutics, Inc. (NASDAQ:PTCT) and Insys Therapeutics Inc (NASDAQ:INSY) Face Securities Class Action Lawsuits
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.